nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—VEGFA—muscle cancer	0.512	1	CbGaD
Carvedilol—XDH—Doxorubicin—muscle cancer	0.0557	0.194	CbGbCtD
Carvedilol—CYP1A1—Dacarbazine—muscle cancer	0.0487	0.17	CbGbCtD
Carvedilol—CYP2E1—Dacarbazine—muscle cancer	0.0376	0.131	CbGbCtD
Carvedilol—PTGS1—Etoposide—muscle cancer	0.0238	0.0831	CbGbCtD
Carvedilol—CYP1A2—Dacarbazine—muscle cancer	0.0218	0.0759	CbGbCtD
Carvedilol—CYP2E1—Etoposide—muscle cancer	0.0184	0.0642	CbGbCtD
Carvedilol—ABCB1—Dactinomycin—muscle cancer	0.0165	0.0576	CbGbCtD
Carvedilol—CYP1A2—Etoposide—muscle cancer	0.0106	0.0371	CbGbCtD
Carvedilol—ABCB1—Vincristine—muscle cancer	0.0102	0.0354	CbGbCtD
Carvedilol—ABCB1—Etoposide—muscle cancer	0.00931	0.0325	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—muscle cancer	0.00635	0.0222	CbGbCtD
Carvedilol—ABCB1—Methotrexate—muscle cancer	0.00615	0.0215	CbGbCtD
Carvedilol—CYP3A4—Vincristine—muscle cancer	0.00609	0.0212	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—muscle cancer	0.00598	0.0209	CbGbCtD
Carvedilol—CYP3A4—Etoposide—muscle cancer	0.00558	0.0195	CbGbCtD
Carvedilol—CYP3A4—Doxorubicin—muscle cancer	0.0038	0.0133	CbGbCtD
Carvedilol—GJA1—Vinorelbine—Vincristine—muscle cancer	0.00241	1	CbGdCrCtD
Carvedilol—NPPB—smooth muscle tissue—muscle cancer	0.00226	0.0339	CbGeAlD
Carvedilol—NPPB—cardiac atrium—muscle cancer	0.00195	0.0292	CbGeAlD
Carvedilol—HIF1A—embryo—muscle cancer	0.00172	0.0258	CbGeAlD
Carvedilol—GJA1—embryo—muscle cancer	0.00167	0.025	CbGeAlD
Carvedilol—SELE—smooth muscle tissue—muscle cancer	0.00153	0.0229	CbGeAlD
Carvedilol—SELE—renal system—muscle cancer	0.00147	0.0221	CbGeAlD
Carvedilol—NPPB—head—muscle cancer	0.00146	0.0218	CbGeAlD
Carvedilol—VCAM1—smooth muscle tissue—muscle cancer	0.0014	0.0211	CbGeAlD
Carvedilol—VCAM1—renal system—muscle cancer	0.00135	0.0203	CbGeAlD
Carvedilol—HIF1A—smooth muscle tissue—muscle cancer	0.00135	0.0203	CbGeAlD
Carvedilol—GJA1—smooth muscle tissue—muscle cancer	0.00131	0.0197	CbGeAlD
Carvedilol—HIF1A—renal system—muscle cancer	0.0013	0.0195	CbGeAlD
Carvedilol—GJA1—renal system—muscle cancer	0.00126	0.0189	CbGeAlD
Carvedilol—VCAM1—cardiac atrium—muscle cancer	0.00121	0.0182	CbGeAlD
Carvedilol—HIF1A—cardiac atrium—muscle cancer	0.00117	0.0175	CbGeAlD
Carvedilol—SELE—tendon—muscle cancer	0.00115	0.0172	CbGeAlD
Carvedilol—GJA1—cardiac atrium—muscle cancer	0.00113	0.017	CbGeAlD
Carvedilol—NDUFC2—renal system—muscle cancer	0.0011	0.0165	CbGeAlD
Carvedilol—SELE—vagina—muscle cancer	0.00106	0.016	CbGeAlD
Carvedilol—VCAM1—tendon—muscle cancer	0.00106	0.0158	CbGeAlD
Carvedilol—VEGFA—smooth muscle tissue—muscle cancer	0.00104	0.0155	CbGeAlD
Carvedilol—VCAM1—bone marrow—muscle cancer	0.00102	0.0153	CbGeAlD
Carvedilol—HIF1A—tendon—muscle cancer	0.00102	0.0152	CbGeAlD
Carvedilol—GJA1—tendon—muscle cancer	0.000985	0.0148	CbGeAlD
Carvedilol—NDUFC2—cardiac atrium—muscle cancer	0.000984	0.0148	CbGeAlD
Carvedilol—HIF1A—bone marrow—muscle cancer	0.000984	0.0148	CbGeAlD
Carvedilol—SELE—head—muscle cancer	0.000984	0.0148	CbGeAlD
Carvedilol—VCAM1—vagina—muscle cancer	0.000979	0.0147	CbGeAlD
Carvedilol—GJA1—bone marrow—muscle cancer	0.000954	0.0143	CbGeAlD
Carvedilol—SELE—testis—muscle cancer	0.00095	0.0143	CbGeAlD
Carvedilol—HIF1A—vagina—muscle cancer	0.000942	0.0141	CbGeAlD
Carvedilol—GJA1—vagina—muscle cancer	0.000914	0.0137	CbGeAlD
Carvedilol—VCAM1—head—muscle cancer	0.000905	0.0136	CbGeAlD
Carvedilol—VEGFA—cardiac atrium—muscle cancer	0.000892	0.0134	CbGeAlD
Carvedilol—XDH—renal system—muscle cancer	0.000887	0.0133	CbGeAlD
Carvedilol—VCAM1—testis—muscle cancer	0.000874	0.0131	CbGeAlD
Carvedilol—HIF1A—head—muscle cancer	0.00087	0.0131	CbGeAlD
Carvedilol—NDUFC2—tendon—muscle cancer	0.000857	0.0129	CbGeAlD
Carvedilol—GJA1—head—muscle cancer	0.000844	0.0127	CbGeAlD
Carvedilol—HIF1A—testis—muscle cancer	0.000841	0.0126	CbGeAlD
Carvedilol—NDUFC2—bone marrow—muscle cancer	0.000831	0.0125	CbGeAlD
Carvedilol—GJA1—testis—muscle cancer	0.000816	0.0122	CbGeAlD
Carvedilol—NDUFC2—vagina—muscle cancer	0.000796	0.0119	CbGeAlD
Carvedilol—VEGFA—tendon—muscle cancer	0.000778	0.0117	CbGeAlD
Carvedilol—VEGFA—bone marrow—muscle cancer	0.000753	0.0113	CbGeAlD
Carvedilol—NDUFC2—head—muscle cancer	0.000735	0.011	CbGeAlD
Carvedilol—VEGFA—vagina—muscle cancer	0.000722	0.0108	CbGeAlD
Carvedilol—NDUFC2—testis—muscle cancer	0.00071	0.0107	CbGeAlD
Carvedilol—ADRA1B—renal system—muscle cancer	0.000666	0.00999	CbGeAlD
Carvedilol—VEGFA—testis—muscle cancer	0.000644	0.00966	CbGeAlD
Carvedilol—XDH—vagina—muscle cancer	0.000642	0.00964	CbGeAlD
Carvedilol—ADRA1B—head—muscle cancer	0.000445	0.00668	CbGeAlD
Carvedilol—ADRA1D—head—muscle cancer	0.000436	0.00654	CbGeAlD
Carvedilol—ADRB1—cardiac atrium—muscle cancer	0.000424	0.00635	CbGeAlD
Carvedilol—ADRA1A—renal system—muscle cancer	0.000374	0.00561	CbGeAlD
Carvedilol—KCNH2—renal system—muscle cancer	0.000361	0.00542	CbGeAlD
Carvedilol—ADRA2C—renal system—muscle cancer	0.000356	0.00535	CbGeAlD
Carvedilol—KCNH2—cardiac atrium—muscle cancer	0.000323	0.00485	CbGeAlD
Carvedilol—ADRA2C—cardiac atrium—muscle cancer	0.000319	0.00479	CbGeAlD
Carvedilol—ADRB1—head—muscle cancer	0.000316	0.00475	CbGeAlD
Carvedilol—CYP1A2—renal system—muscle cancer	0.000309	0.00464	CbGeAlD
Carvedilol—CYP1A1—renal system—muscle cancer	0.000305	0.00458	CbGeAlD
Carvedilol—PTGS1—smooth muscle tissue—muscle cancer	0.000278	0.00418	CbGeAlD
Carvedilol—CYP2E1—renal system—muscle cancer	0.000278	0.00417	CbGeAlD
Carvedilol—ADRA2C—tendon—muscle cancer	0.000278	0.00417	CbGeAlD
Carvedilol—CYP1A1—cardiac atrium—muscle cancer	0.000273	0.0041	CbGeAlD
Carvedilol—KCNH2—bone marrow—muscle cancer	0.000273	0.0041	CbGeAlD
Carvedilol—PTGS1—renal system—muscle cancer	0.000268	0.00402	CbGeAlD
Carvedilol—KCNH2—vagina—muscle cancer	0.000262	0.00392	CbGeAlD
Carvedilol—ADRA2C—vagina—muscle cancer	0.000258	0.00387	CbGeAlD
Carvedilol—ADRA2A—cardiac atrium—muscle cancer	0.000255	0.00382	CbGeAlD
Carvedilol—ADRA1A—head—muscle cancer	0.00025	0.00375	CbGeAlD
Carvedilol—KCNH2—head—muscle cancer	0.000242	0.00363	CbGeAlD
Carvedilol—PTGS1—cardiac atrium—muscle cancer	0.00024	0.0036	CbGeAlD
Carvedilol—ADRA2C—head—muscle cancer	0.000238	0.00358	CbGeAlD
Carvedilol—KCNH2—testis—muscle cancer	0.000233	0.0035	CbGeAlD
Carvedilol—ADRA2C—testis—muscle cancer	0.00023	0.00346	CbGeAlD
Carvedilol—CYP3A4—renal system—muscle cancer	0.000224	0.00336	CbGeAlD
Carvedilol—ADRA2A—tendon—muscle cancer	0.000222	0.00333	CbGeAlD
Carvedilol—CYP1A1—vagina—muscle cancer	0.000221	0.00331	CbGeAlD
Carvedilol—CYP2D6—renal system—muscle cancer	0.00022	0.0033	CbGeAlD
Carvedilol—CYP2E1—tendon—muscle cancer	0.000217	0.00326	CbGeAlD
Carvedilol—ABCB1—embryo—muscle cancer	0.000209	0.00314	CbGeAlD
Carvedilol—PTGS1—tendon—muscle cancer	0.000209	0.00314	CbGeAlD
Carvedilol—ADRA2A—vagina—muscle cancer	0.000206	0.00309	CbGeAlD
Carvedilol—CYP1A1—head—muscle cancer	0.000204	0.00306	CbGeAlD
Carvedilol—PTGS1—vagina—muscle cancer	0.000194	0.00291	CbGeAlD
Carvedilol—ADRA2A—head—muscle cancer	0.00019	0.00285	CbGeAlD
Carvedilol—CYP2E1—head—muscle cancer	0.000186	0.00279	CbGeAlD
Carvedilol—ADRA2A—testis—muscle cancer	0.000184	0.00276	CbGeAlD
Carvedilol—CYP2E1—testis—muscle cancer	0.00018	0.0027	CbGeAlD
Carvedilol—PTGS1—head—muscle cancer	0.000179	0.00269	CbGeAlD
Carvedilol—PTGS1—testis—muscle cancer	0.000173	0.0026	CbGeAlD
Carvedilol—ABCB1—renal system—muscle cancer	0.000158	0.00238	CbGeAlD
Carvedilol—Malaise—Etoposide—muscle cancer	0.000154	0.00214	CcSEcCtD
Carvedilol—Vertigo—Etoposide—muscle cancer	0.000153	0.00213	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000153	0.00212	CcSEcCtD
Carvedilol—Leukopenia—Etoposide—muscle cancer	0.000153	0.00212	CcSEcCtD
Carvedilol—Purpura—Doxorubicin—muscle cancer	0.000153	0.00212	CcSEcCtD
Carvedilol—Abdominal pain—Dactinomycin—muscle cancer	0.000152	0.00211	CcSEcCtD
Carvedilol—Body temperature increased—Dactinomycin—muscle cancer	0.000152	0.00211	CcSEcCtD
Carvedilol—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.000152	0.00211	CcSEcCtD
Carvedilol—Hypoglycaemia—Doxorubicin—muscle cancer	0.000151	0.00209	CcSEcCtD
Carvedilol—Cardiac failure—Doxorubicin—muscle cancer	0.000151	0.00209	CcSEcCtD
Carvedilol—Loss of consciousness—Etoposide—muscle cancer	0.00015	0.00208	CcSEcCtD
Carvedilol—Cerebrovascular accident—Doxorubicin—muscle cancer	0.00015	0.00208	CcSEcCtD
Carvedilol—Decreased appetite—Vincristine—muscle cancer	0.00015	0.00207	CcSEcCtD
Carvedilol—Cough—Etoposide—muscle cancer	0.000149	0.00207	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Vincristine—muscle cancer	0.000149	0.00206	CcSEcCtD
Carvedilol—Fatigue—Vincristine—muscle cancer	0.000148	0.00206	CcSEcCtD
Carvedilol—Convulsion—Etoposide—muscle cancer	0.000148	0.00205	CcSEcCtD
Carvedilol—Hyponatraemia—Doxorubicin—muscle cancer	0.000148	0.00205	CcSEcCtD
Carvedilol—Hypertension—Etoposide—muscle cancer	0.000147	0.00204	CcSEcCtD
Carvedilol—CYP2D6—head—muscle cancer	0.000147	0.00221	CbGeAlD
Carvedilol—Constipation—Vincristine—muscle cancer	0.000147	0.00204	CcSEcCtD
Carvedilol—Pain—Vincristine—muscle cancer	0.000147	0.00204	CcSEcCtD
Carvedilol—Pain in extremity—Doxorubicin—muscle cancer	0.000147	0.00204	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000147	0.00204	CcSEcCtD
Carvedilol—Chest pain—Etoposide—muscle cancer	0.000145	0.00202	CcSEcCtD
Carvedilol—Affect lability—Doxorubicin—muscle cancer	0.000145	0.00201	CcSEcCtD
Carvedilol—Migraine—Doxorubicin—muscle cancer	0.000145	0.00201	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000144	0.002	CcSEcCtD
Carvedilol—Discomfort—Etoposide—muscle cancer	0.000144	0.00199	CcSEcCtD
Carvedilol—CYP2D6—testis—muscle cancer	0.000142	0.00214	CbGeAlD
Carvedilol—Hypersensitivity—Dactinomycin—muscle cancer	0.000142	0.00197	CcSEcCtD
Carvedilol—Gastrointestinal pain—Vincristine—muscle cancer	0.000141	0.00195	CcSEcCtD
Carvedilol—Confusional state—Etoposide—muscle cancer	0.000141	0.00195	CcSEcCtD
Carvedilol—Cardiac arrest—Doxorubicin—muscle cancer	0.00014	0.00194	CcSEcCtD
Carvedilol—Pancytopenia—Methotrexate—muscle cancer	0.000139	0.00193	CcSEcCtD
Carvedilol—Anaphylactic shock—Etoposide—muscle cancer	0.000139	0.00193	CcSEcCtD
Carvedilol—Mood swings—Doxorubicin—muscle cancer	0.000139	0.00193	CcSEcCtD
Carvedilol—Infection—Etoposide—muscle cancer	0.000138	0.00192	CcSEcCtD
Carvedilol—Asthenia—Dactinomycin—muscle cancer	0.000138	0.00192	CcSEcCtD
Carvedilol—Blood creatinine increased—Doxorubicin—muscle cancer	0.000138	0.00191	CcSEcCtD
Carvedilol—Dehydration—Doxorubicin—muscle cancer	0.000137	0.0019	CcSEcCtD
Carvedilol—Thrombocytopenia—Etoposide—muscle cancer	0.000136	0.00189	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000136	0.00189	CcSEcCtD
Carvedilol—Tachycardia—Etoposide—muscle cancer	0.000136	0.00189	CcSEcCtD
Carvedilol—Abdominal pain—Vincristine—muscle cancer	0.000136	0.00189	CcSEcCtD
Carvedilol—Body temperature increased—Vincristine—muscle cancer	0.000136	0.00189	CcSEcCtD
Carvedilol—Skin disorder—Etoposide—muscle cancer	0.000135	0.00188	CcSEcCtD
Carvedilol—Erectile dysfunction—Methotrexate—muscle cancer	0.000135	0.00188	CcSEcCtD
Carvedilol—Hyperhidrosis—Etoposide—muscle cancer	0.000135	0.00187	CcSEcCtD
Carvedilol—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000134	0.00186	CcSEcCtD
Carvedilol—Photosensitivity reaction—Methotrexate—muscle cancer	0.000134	0.00186	CcSEcCtD
Carvedilol—Hypokalaemia—Doxorubicin—muscle cancer	0.000134	0.00186	CcSEcCtD
Carvedilol—Anorexia—Etoposide—muscle cancer	0.000133	0.00184	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000132	0.00184	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000132	0.00184	CcSEcCtD
Carvedilol—Diarrhoea—Dactinomycin—muscle cancer	0.000132	0.00183	CcSEcCtD
Carvedilol—Pneumonia—Methotrexate—muscle cancer	0.000132	0.00183	CcSEcCtD
Carvedilol—Nasopharyngitis—Doxorubicin—muscle cancer	0.000132	0.00182	CcSEcCtD
Carvedilol—Depression—Methotrexate—muscle cancer	0.000131	0.00181	CcSEcCtD
Carvedilol—Hypotension—Etoposide—muscle cancer	0.00013	0.00181	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00013	0.0018	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00013	0.0018	CcSEcCtD
Carvedilol—Renal failure—Methotrexate—muscle cancer	0.000129	0.00178	CcSEcCtD
Carvedilol—Influenza—Doxorubicin—muscle cancer	0.000127	0.00176	CcSEcCtD
Carvedilol—Hypersensitivity—Vincristine—muscle cancer	0.000127	0.00176	CcSEcCtD
Carvedilol—Paraesthesia—Etoposide—muscle cancer	0.000125	0.00174	CcSEcCtD
Carvedilol—Haematuria—Methotrexate—muscle cancer	0.000125	0.00173	CcSEcCtD
Carvedilol—Dyspnoea—Etoposide—muscle cancer	0.000124	0.00172	CcSEcCtD
Carvedilol—Somnolence—Etoposide—muscle cancer	0.000124	0.00172	CcSEcCtD
Carvedilol—Angina pectoris—Doxorubicin—muscle cancer	0.000124	0.00172	CcSEcCtD
Carvedilol—Asthenia—Vincristine—muscle cancer	0.000123	0.00171	CcSEcCtD
Carvedilol—Vomiting—Dactinomycin—muscle cancer	0.000122	0.0017	CcSEcCtD
Carvedilol—Bronchitis—Doxorubicin—muscle cancer	0.000122	0.0017	CcSEcCtD
Carvedilol—Rash—Dactinomycin—muscle cancer	0.000121	0.00168	CcSEcCtD
Carvedilol—Decreased appetite—Etoposide—muscle cancer	0.000121	0.00168	CcSEcCtD
Carvedilol—Pancytopenia—Doxorubicin—muscle cancer	0.000121	0.00167	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Etoposide—muscle cancer	0.00012	0.00167	CcSEcCtD
Carvedilol—Fatigue—Etoposide—muscle cancer	0.00012	0.00167	CcSEcCtD
Carvedilol—ABCB1—bone marrow—muscle cancer	0.00012	0.0018	CbGeAlD
Carvedilol—Pain—Etoposide—muscle cancer	0.000119	0.00165	CcSEcCtD
Carvedilol—Constipation—Etoposide—muscle cancer	0.000119	0.00165	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000118	0.00164	CcSEcCtD
Carvedilol—Haemoglobin—Methotrexate—muscle cancer	0.000118	0.00164	CcSEcCtD
Carvedilol—Diarrhoea—Vincristine—muscle cancer	0.000118	0.00163	CcSEcCtD
Carvedilol—Haemorrhage—Methotrexate—muscle cancer	0.000117	0.00163	CcSEcCtD
Carvedilol—Pollakiuria—Doxorubicin—muscle cancer	0.000117	0.00163	CcSEcCtD
Carvedilol—Pharyngitis—Methotrexate—muscle cancer	0.000117	0.00162	CcSEcCtD
Carvedilol—Urinary tract disorder—Methotrexate—muscle cancer	0.000116	0.00161	CcSEcCtD
Carvedilol—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000116	0.00161	CcSEcCtD
Carvedilol—Weight increased—Doxorubicin—muscle cancer	0.000116	0.0016	CcSEcCtD
Carvedilol—Urethral disorder—Methotrexate—muscle cancer	0.000115	0.0016	CcSEcCtD
Carvedilol—Weight decreased—Doxorubicin—muscle cancer	0.000115	0.00159	CcSEcCtD
Carvedilol—Feeling abnormal—Etoposide—muscle cancer	0.000115	0.00159	CcSEcCtD
Carvedilol—ABCB1—vagina—muscle cancer	0.000115	0.00172	CbGeAlD
Carvedilol—Hyperglycaemia—Doxorubicin—muscle cancer	0.000115	0.00159	CcSEcCtD
Carvedilol—Nausea—Dactinomycin—muscle cancer	0.000114	0.00159	CcSEcCtD
Carvedilol—Pneumonia—Doxorubicin—muscle cancer	0.000114	0.00158	CcSEcCtD
Carvedilol—Gastrointestinal pain—Etoposide—muscle cancer	0.000114	0.00158	CcSEcCtD
Carvedilol—Dizziness—Vincristine—muscle cancer	0.000114	0.00158	CcSEcCtD
Carvedilol—Visual impairment—Methotrexate—muscle cancer	0.000113	0.00157	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000112	0.00156	CcSEcCtD
Carvedilol—Renal failure—Doxorubicin—muscle cancer	0.000111	0.00155	CcSEcCtD
Carvedilol—Erythema multiforme—Methotrexate—muscle cancer	0.000111	0.00154	CcSEcCtD
Carvedilol—Urticaria—Etoposide—muscle cancer	0.000111	0.00154	CcSEcCtD
Carvedilol—Abdominal pain—Etoposide—muscle cancer	0.00011	0.00153	CcSEcCtD
Carvedilol—Body temperature increased—Etoposide—muscle cancer	0.00011	0.00153	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—muscle cancer	0.00011	0.00153	CcSEcCtD
Carvedilol—Tinnitus—Methotrexate—muscle cancer	0.00011	0.00152	CcSEcCtD
Carvedilol—Vomiting—Vincristine—muscle cancer	0.000109	0.00152	CcSEcCtD
Carvedilol—Rash—Vincristine—muscle cancer	0.000108	0.0015	CcSEcCtD
Carvedilol—Dermatitis—Vincristine—muscle cancer	0.000108	0.0015	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—muscle cancer	0.000108	0.0015	CcSEcCtD
Carvedilol—Headache—Vincristine—muscle cancer	0.000108	0.00149	CcSEcCtD
Carvedilol—Angiopathy—Methotrexate—muscle cancer	0.000107	0.00148	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—muscle cancer	0.000106	0.00147	CcSEcCtD
Carvedilol—Immune system disorder—Methotrexate—muscle cancer	0.000106	0.00147	CcSEcCtD
Carvedilol—ABCB1—head—muscle cancer	0.000106	0.00159	CbGeAlD
Carvedilol—Mediastinal disorder—Methotrexate—muscle cancer	0.000106	0.00147	CcSEcCtD
Carvedilol—Alopecia—Methotrexate—muscle cancer	0.000104	0.00144	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—muscle cancer	0.000104	0.00144	CcSEcCtD
Carvedilol—Hypersensitivity—Etoposide—muscle cancer	0.000103	0.00142	CcSEcCtD
Carvedilol—ABCB1—testis—muscle cancer	0.000102	0.00154	CbGeAlD
Carvedilol—Malnutrition—Methotrexate—muscle cancer	0.000102	0.00142	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—muscle cancer	0.000102	0.00142	CcSEcCtD
Carvedilol—Nausea—Vincristine—muscle cancer	0.000102	0.00142	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—muscle cancer	0.000102	0.00141	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—muscle cancer	0.000102	0.00141	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—muscle cancer	0.000101	0.0014	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—muscle cancer	0.000101	0.0014	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—muscle cancer	0.0001	0.00139	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—muscle cancer	0.0001	0.00139	CcSEcCtD
Carvedilol—Asthenia—Etoposide—muscle cancer	0.0001	0.00139	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—muscle cancer	9.97e-05	0.00138	CcSEcCtD
Carvedilol—Back pain—Methotrexate—muscle cancer	9.89e-05	0.00137	CcSEcCtD
Carvedilol—Pruritus—Etoposide—muscle cancer	9.86e-05	0.00137	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—muscle cancer	9.8e-05	0.00136	CcSEcCtD
Carvedilol—Vision blurred—Methotrexate—muscle cancer	9.64e-05	0.00134	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—muscle cancer	9.62e-05	0.00133	CcSEcCtD
Carvedilol—Diarrhoea—Etoposide—muscle cancer	9.54e-05	0.00132	CcSEcCtD
Carvedilol—Ill-defined disorder—Methotrexate—muscle cancer	9.49e-05	0.00132	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—muscle cancer	9.49e-05	0.00132	CcSEcCtD
Carvedilol—Anaemia—Methotrexate—muscle cancer	9.45e-05	0.00131	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—muscle cancer	9.23e-05	0.00128	CcSEcCtD
Carvedilol—Malaise—Methotrexate—muscle cancer	9.22e-05	0.00128	CcSEcCtD
Carvedilol—Dizziness—Etoposide—muscle cancer	9.22e-05	0.00128	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—muscle cancer	9.19e-05	0.00127	CcSEcCtD
Carvedilol—Vertigo—Methotrexate—muscle cancer	9.19e-05	0.00127	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—muscle cancer	9.17e-05	0.00127	CcSEcCtD
Carvedilol—Leukopenia—Methotrexate—muscle cancer	9.16e-05	0.00127	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—muscle cancer	8.99e-05	0.00125	CcSEcCtD
Carvedilol—Cough—Methotrexate—muscle cancer	8.93e-05	0.00124	CcSEcCtD
Carvedilol—Convulsion—Methotrexate—muscle cancer	8.86e-05	0.00123	CcSEcCtD
Carvedilol—Vomiting—Etoposide—muscle cancer	8.86e-05	0.00123	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—muscle cancer	8.86e-05	0.00123	CcSEcCtD
Carvedilol—Rash—Etoposide—muscle cancer	8.79e-05	0.00122	CcSEcCtD
Carvedilol—Dermatitis—Etoposide—muscle cancer	8.78e-05	0.00122	CcSEcCtD
Carvedilol—Headache—Etoposide—muscle cancer	8.73e-05	0.00121	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—muscle cancer	8.73e-05	0.00121	CcSEcCtD
Carvedilol—Arthralgia—Methotrexate—muscle cancer	8.71e-05	0.00121	CcSEcCtD
Carvedilol—Chest pain—Methotrexate—muscle cancer	8.71e-05	0.00121	CcSEcCtD
Carvedilol—Myalgia—Methotrexate—muscle cancer	8.71e-05	0.00121	CcSEcCtD
Carvedilol—Tension—Doxorubicin—muscle cancer	8.69e-05	0.00121	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	8.65e-05	0.0012	CcSEcCtD
Carvedilol—Discomfort—Methotrexate—muscle cancer	8.6e-05	0.00119	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—muscle cancer	8.6e-05	0.00119	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—muscle cancer	8.57e-05	0.00119	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—muscle cancer	8.51e-05	0.00118	CcSEcCtD
Carvedilol—Confusional state—Methotrexate—muscle cancer	8.42e-05	0.00117	CcSEcCtD
Carvedilol—Anaphylactic shock—Methotrexate—muscle cancer	8.35e-05	0.00116	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—muscle cancer	8.35e-05	0.00116	CcSEcCtD
Carvedilol—Infection—Methotrexate—muscle cancer	8.29e-05	0.00115	CcSEcCtD
Carvedilol—Nausea—Etoposide—muscle cancer	8.28e-05	0.00115	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—muscle cancer	8.22e-05	0.00114	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—muscle cancer	8.19e-05	0.00114	CcSEcCtD
Carvedilol—Thrombocytopenia—Methotrexate—muscle cancer	8.17e-05	0.00113	CcSEcCtD
Carvedilol—Skin disorder—Methotrexate—muscle cancer	8.11e-05	0.00112	CcSEcCtD
Carvedilol—Hyperhidrosis—Methotrexate—muscle cancer	8.07e-05	0.00112	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—muscle cancer	7.99e-05	0.00111	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—muscle cancer	7.96e-05	0.0011	CcSEcCtD
Carvedilol—Anorexia—Methotrexate—muscle cancer	7.96e-05	0.0011	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—muscle cancer	7.94e-05	0.0011	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—muscle cancer	7.93e-05	0.0011	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—muscle cancer	7.83e-05	0.00109	CcSEcCtD
Carvedilol—Hypotension—Methotrexate—muscle cancer	7.8e-05	0.00108	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—muscle cancer	7.78e-05	0.00108	CcSEcCtD
Carvedilol—Cough—Doxorubicin—muscle cancer	7.73e-05	0.00107	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—muscle cancer	7.67e-05	0.00106	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—muscle cancer	7.65e-05	0.00106	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methotrexate—muscle cancer	7.61e-05	0.00105	CcSEcCtD
Carvedilol—Insomnia—Methotrexate—muscle cancer	7.55e-05	0.00105	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—muscle cancer	7.54e-05	0.00105	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—muscle cancer	7.54e-05	0.00105	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—muscle cancer	7.54e-05	0.00105	CcSEcCtD
Carvedilol—Paraesthesia—Methotrexate—muscle cancer	7.5e-05	0.00104	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	7.49e-05	0.00104	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—muscle cancer	7.45e-05	0.00103	CcSEcCtD
Carvedilol—Dyspnoea—Methotrexate—muscle cancer	7.44e-05	0.00103	CcSEcCtD
Carvedilol—Somnolence—Methotrexate—muscle cancer	7.42e-05	0.00103	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—muscle cancer	7.37e-05	0.00102	CcSEcCtD
Carvedilol—Dyspepsia—Methotrexate—muscle cancer	7.35e-05	0.00102	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—muscle cancer	7.29e-05	0.00101	CcSEcCtD
Carvedilol—Decreased appetite—Methotrexate—muscle cancer	7.26e-05	0.00101	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—muscle cancer	7.23e-05	0.001	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—muscle cancer	7.23e-05	0.001	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Methotrexate—muscle cancer	7.21e-05	0.001	CcSEcCtD
Carvedilol—Fatigue—Methotrexate—muscle cancer	7.2e-05	0.000998	CcSEcCtD
Carvedilol—Infection—Doxorubicin—muscle cancer	7.18e-05	0.000996	CcSEcCtD
Carvedilol—Pain—Methotrexate—muscle cancer	7.14e-05	0.00099	CcSEcCtD
Carvedilol—Shock—Doxorubicin—muscle cancer	7.11e-05	0.000986	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—muscle cancer	7.08e-05	0.000982	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—muscle cancer	7.05e-05	0.000978	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—muscle cancer	7.02e-05	0.000974	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—muscle cancer	6.99e-05	0.000969	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—muscle cancer	6.89e-05	0.000956	CcSEcCtD
Carvedilol—Feeling abnormal—Methotrexate—muscle cancer	6.88e-05	0.000954	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methotrexate—muscle cancer	6.83e-05	0.000947	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—muscle cancer	6.75e-05	0.000937	CcSEcCtD
Carvedilol—Urticaria—Methotrexate—muscle cancer	6.63e-05	0.00092	CcSEcCtD
Carvedilol—Abdominal pain—Methotrexate—muscle cancer	6.6e-05	0.000915	CcSEcCtD
Carvedilol—Body temperature increased—Methotrexate—muscle cancer	6.6e-05	0.000915	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—muscle cancer	6.59e-05	0.000913	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—muscle cancer	6.54e-05	0.000907	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—muscle cancer	6.49e-05	0.0009	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—muscle cancer	6.44e-05	0.000894	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—muscle cancer	6.43e-05	0.000891	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—muscle cancer	6.36e-05	0.000882	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—muscle cancer	6.28e-05	0.000871	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—muscle cancer	6.24e-05	0.000865	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—muscle cancer	6.23e-05	0.000864	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—muscle cancer	6.18e-05	0.000857	CcSEcCtD
Carvedilol—Pain—Doxorubicin—muscle cancer	6.18e-05	0.000857	CcSEcCtD
Carvedilol—Hypersensitivity—Methotrexate—muscle cancer	6.15e-05	0.000853	CcSEcCtD
Carvedilol—Asthenia—Methotrexate—muscle cancer	5.99e-05	0.000831	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—muscle cancer	5.96e-05	0.000826	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—muscle cancer	5.91e-05	0.00082	CcSEcCtD
Carvedilol—Pruritus—Methotrexate—muscle cancer	5.91e-05	0.000819	CcSEcCtD
Carvedilol—ADRA2A—G alpha (i) signalling events—CNR1—muscle cancer	5.86e-05	0.000967	CbGpPWpGaD
Carvedilol—ADRA1A—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	5.85e-05	0.000965	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—IGF2—muscle cancer	5.8e-05	0.000957	CbGpPWpGaD
Carvedilol—Urticaria—Doxorubicin—muscle cancer	5.74e-05	0.000796	CcSEcCtD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	5.73e-05	0.000946	CbGpPWpGaD
Carvedilol—Abdominal pain—Doxorubicin—muscle cancer	5.71e-05	0.000792	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—muscle cancer	5.71e-05	0.000792	CcSEcCtD
Carvedilol—Diarrhoea—Methotrexate—muscle cancer	5.71e-05	0.000792	CcSEcCtD
Carvedilol—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	5.68e-05	0.000937	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—FOXO4—muscle cancer	5.67e-05	0.000937	CbGpPWpGaD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—VEGFA—muscle cancer	5.65e-05	0.000933	CbGpPWpGaD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	5.64e-05	0.000931	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—PTCH1—muscle cancer	5.59e-05	0.000922	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—KIT—muscle cancer	5.57e-05	0.00092	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—CNR1—muscle cancer	5.57e-05	0.000919	CbGpPWpGaD
Carvedilol—VEGFA—Cellular responses to stress—CDKN2A—muscle cancer	5.55e-05	0.000917	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—PTCH1—muscle cancer	5.54e-05	0.000914	CbGpPWpGaD
Carvedilol—Dizziness—Methotrexate—muscle cancer	5.52e-05	0.000766	CcSEcCtD
Carvedilol—ADRB2—GPCR ligand binding—PTCH1—muscle cancer	5.46e-05	0.000902	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—FOXO1—muscle cancer	5.44e-05	0.000898	CbGpPWpGaD
Carvedilol—ADRA2A—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	5.43e-05	0.000897	CbGpPWpGaD
Carvedilol—VEGFA—Cellular responses to stress—MDM2—muscle cancer	5.39e-05	0.000889	CbGpPWpGaD
Carvedilol—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	5.38e-05	0.000888	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—ANGPT2—muscle cancer	5.33e-05	0.00088	CbGpPWpGaD
Carvedilol—Hypersensitivity—Doxorubicin—muscle cancer	5.33e-05	0.000739	CcSEcCtD
Carvedilol—Vomiting—Methotrexate—muscle cancer	5.31e-05	0.000736	CcSEcCtD
Carvedilol—Rash—Methotrexate—muscle cancer	5.26e-05	0.00073	CcSEcCtD
Carvedilol—Dermatitis—Methotrexate—muscle cancer	5.26e-05	0.000729	CcSEcCtD
Carvedilol—Headache—Methotrexate—muscle cancer	5.23e-05	0.000725	CcSEcCtD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	5.19e-05	0.000856	CbGpPWpGaD
Carvedilol—Asthenia—Doxorubicin—muscle cancer	5.19e-05	0.000719	CcSEcCtD
Carvedilol—ADRA1D—GPCR ligand binding—CNR1—muscle cancer	5.18e-05	0.000854	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—PTCH1—muscle cancer	5.17e-05	0.000854	CbGpPWpGaD
Carvedilol—Pruritus—Doxorubicin—muscle cancer	5.11e-05	0.000709	CcSEcCtD
Carvedilol—ADRA1B—GPCR ligand binding—PTCH1—muscle cancer	5.09e-05	0.00084	CbGpPWpGaD
Carvedilol—ADRA2A—Platelet activation, signaling and aggregation—IGF2—muscle cancer	5.03e-05	0.00083	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	5.01e-05	0.000827	CbGpPWpGaD
Carvedilol—Nausea—Methotrexate—muscle cancer	4.96e-05	0.000688	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—muscle cancer	4.95e-05	0.000686	CcSEcCtD
Carvedilol—ADRA1B—AMPK Signaling—TP53—muscle cancer	4.9e-05	0.000809	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	4.87e-05	0.000804	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.86e-05	0.000803	CbGpPWpGaD
Carvedilol—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	4.85e-05	0.000801	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Breast Cancer Pathway—TP53—muscle cancer	4.83e-05	0.000798	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—PTCH1—muscle cancer	4.83e-05	0.000797	CbGpPWpGaD
Carvedilol—Dizziness—Doxorubicin—muscle cancer	4.78e-05	0.000663	CcSEcCtD
Carvedilol—ADRA1D—Signaling Pathways—KIDINS220—muscle cancer	4.72e-05	0.00078	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—CNR1—muscle cancer	4.72e-05	0.000778	CbGpPWpGaD
Carvedilol—KCNH2—Neuronal System—MDM2—muscle cancer	4.67e-05	0.000772	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—CNR1—muscle cancer	4.67e-05	0.000771	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	4.66e-05	0.000769	CbGpPWpGaD
Carvedilol—XDH—Metabolism—MED12—muscle cancer	4.62e-05	0.000763	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—CNR1—muscle cancer	4.61e-05	0.000762	CbGpPWpGaD
Carvedilol—Vomiting—Doxorubicin—muscle cancer	4.6e-05	0.000637	CcSEcCtD
Carvedilol—HIF1A—Disease—KIT—muscle cancer	4.56e-05	0.000753	CbGpPWpGaD
Carvedilol—Rash—Doxorubicin—muscle cancer	4.56e-05	0.000632	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—muscle cancer	4.55e-05	0.000632	CcSEcCtD
Carvedilol—HIF1A—Signaling Pathways—IGF2—muscle cancer	4.55e-05	0.000752	CbGpPWpGaD
Carvedilol—Headache—Doxorubicin—muscle cancer	4.53e-05	0.000628	CcSEcCtD
Carvedilol—ADRA1A—GPCR ligand binding—PTCH1—muscle cancer	4.52e-05	0.000746	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—CNR1—muscle cancer	4.49e-05	0.000741	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—MDM2—muscle cancer	4.39e-05	0.000725	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—CNR1—muscle cancer	4.36e-05	0.000721	CbGpPWpGaD
Carvedilol—ADRA1A—AMPK Signaling—TP53—muscle cancer	4.35e-05	0.000718	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KIDINS220—muscle cancer	4.3e-05	0.00071	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—CNR1—muscle cancer	4.3e-05	0.000709	CbGpPWpGaD
Carvedilol—Nausea—Doxorubicin—muscle cancer	4.29e-05	0.000595	CcSEcCtD
Carvedilol—ADRA2B—Signaling Pathways—KIDINS220—muscle cancer	4.26e-05	0.000704	CbGpPWpGaD
Carvedilol—XDH—Metabolism—ENO2—muscle cancer	4.22e-05	0.000696	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KIDINS220—muscle cancer	4.21e-05	0.000695	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—PTCH1—muscle cancer	4.2e-05	0.000693	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—FOXO1—muscle cancer	4.19e-05	0.000692	CbGpPWpGaD
Carvedilol—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	4.15e-05	0.000686	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	4.09e-05	0.000675	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—CNR1—muscle cancer	4.08e-05	0.000673	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4e-05	0.000661	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KIDINS220—muscle cancer	3.98e-05	0.000657	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KIDINS220—muscle cancer	3.92e-05	0.000647	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—FH—muscle cancer	3.84e-05	0.000634	CbGpPWpGaD
Carvedilol—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	3.83e-05	0.000633	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—FH—muscle cancer	3.83e-05	0.000633	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—CNR1—muscle cancer	3.82e-05	0.00063	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—PTGS2—muscle cancer	3.76e-05	0.000621	CbGpPWpGaD
Carvedilol—HIF1A—Disease—MDM2—muscle cancer	3.59e-05	0.000593	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—CNR1—muscle cancer	3.55e-05	0.000585	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KIDINS220—muscle cancer	3.48e-05	0.000575	CbGpPWpGaD
Carvedilol—HIF1A—Disease—PTGS2—muscle cancer	3.46e-05	0.000571	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.43e-05	0.000565	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—IGF2—muscle cancer	3.42e-05	0.000564	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—VEGFA—muscle cancer	3.32e-05	0.000548	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KIDINS220—muscle cancer	3.23e-05	0.000534	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—KIT—muscle cancer	3.19e-05	0.000527	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—IGF2—muscle cancer	3.19e-05	0.000527	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—PTCH1—muscle cancer	3.15e-05	0.000519	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—FH—muscle cancer	3.12e-05	0.000515	CbGpPWpGaD
Carvedilol—VEGFA—Cellular responses to stress—TP53—muscle cancer	3.09e-05	0.00051	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—CNR1—muscle cancer	2.92e-05	0.000483	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—PTCH1—muscle cancer	2.87e-05	0.000473	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—FH—muscle cancer	2.86e-05	0.000473	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—PTCH1—muscle cancer	2.85e-05	0.000471	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—PTCH1—muscle cancer	2.85e-05	0.00047	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—PTCH1—muscle cancer	2.84e-05	0.000469	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—PTCH1—muscle cancer	2.8e-05	0.000463	CbGpPWpGaD
Carvedilol—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	2.78e-05	0.000459	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—FH—muscle cancer	2.7e-05	0.000446	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—CNR1—muscle cancer	2.66e-05	0.00044	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—CNR1—muscle cancer	2.66e-05	0.000438	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—PTCH1—muscle cancer	2.65e-05	0.000438	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—CNR1—muscle cancer	2.64e-05	0.000436	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—PTCH1—muscle cancer	2.61e-05	0.000431	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—CNR1—muscle cancer	2.61e-05	0.00043	CbGpPWpGaD
Carvedilol—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	2.6e-05	0.000429	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—IGF2—muscle cancer	2.59e-05	0.000428	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.56e-05	0.000422	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—MDM2—muscle cancer	2.51e-05	0.000415	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—CNR1—muscle cancer	2.47e-05	0.000407	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—FOXO4—muscle cancer	2.45e-05	0.000405	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—FOXO4—muscle cancer	2.45e-05	0.000404	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—CNR1—muscle cancer	2.43e-05	0.000401	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CNR1—muscle cancer	2.42e-05	0.0004	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CNR1—muscle cancer	2.41e-05	0.000398	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CNR1—muscle cancer	2.4e-05	0.000397	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CNR1—muscle cancer	2.4e-05	0.000396	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CNR1—muscle cancer	2.37e-05	0.000391	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PTCH1—muscle cancer	2.32e-05	0.000383	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CNR1—muscle cancer	2.24e-05	0.00037	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CNR1—muscle cancer	2.2e-05	0.000364	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.18e-05	0.000361	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—MED12—muscle cancer	2.17e-05	0.000358	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—MED12—muscle cancer	2.16e-05	0.000357	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	2.16e-05	0.000356	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CNR1—muscle cancer	2.16e-05	0.000356	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—FH—muscle cancer	2.16e-05	0.000356	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PTCH1—muscle cancer	2.16e-05	0.000356	CbGpPWpGaD
Carvedilol—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	2.11e-05	0.000348	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	2.08e-05	0.000343	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—FH—muscle cancer	2.03e-05	0.000335	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—FH—muscle cancer	2.01e-05	0.000333	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CNR1—muscle cancer	2e-05	0.000331	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ENO2—muscle cancer	1.98e-05	0.000326	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ENO2—muscle cancer	1.97e-05	0.000326	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IGF2—muscle cancer	1.97e-05	0.000325	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IGF2—muscle cancer	1.96e-05	0.000324	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CNR1—muscle cancer	1.96e-05	0.000323	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—VEGFA—muscle cancer	1.91e-05	0.000315	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTCH1—muscle cancer	1.86e-05	0.000307	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TP53—muscle cancer	1.84e-05	0.000303	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CNR1—muscle cancer	1.82e-05	0.0003	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—FOXO1—muscle cancer	1.81e-05	0.000299	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—FOXO1—muscle cancer	1.81e-05	0.000299	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—MED12—muscle cancer	1.76e-05	0.000291	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—FH—muscle cancer	1.72e-05	0.000284	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTCH1—muscle cancer	1.69e-05	0.00028	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTCH1—muscle cancer	1.68e-05	0.000277	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTCH1—muscle cancer	1.66e-05	0.000274	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.64e-05	0.000271	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—MED12—muscle cancer	1.62e-05	0.000267	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ENO2—muscle cancer	1.61e-05	0.000265	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—FOXO4—muscle cancer	1.6e-05	0.000264	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CNR1—muscle cancer	1.57e-05	0.000259	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTCH1—muscle cancer	1.57e-05	0.000259	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.54e-05	0.000255	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTCH1—muscle cancer	1.54e-05	0.000255	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—MED12—muscle cancer	1.53e-05	0.000252	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ENO2—muscle cancer	1.47e-05	0.000244	CbGpPWpGaD
Carvedilol—XDH—Metabolism—PTGS2—muscle cancer	1.47e-05	0.000242	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—FOXO4—muscle cancer	1.46e-05	0.00024	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—FOXO4—muscle cancer	1.44e-05	0.000238	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TP53—muscle cancer	1.44e-05	0.000238	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—VEGFA—muscle cancer	1.43e-05	0.000237	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CNR1—muscle cancer	1.43e-05	0.000236	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—FOXO4—muscle cancer	1.42e-05	0.000235	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CNR1—muscle cancer	1.42e-05	0.000234	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CNR1—muscle cancer	1.4e-05	0.000231	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ENO2—muscle cancer	1.39e-05	0.00023	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KIT—muscle cancer	1.38e-05	0.000228	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KIT—muscle cancer	1.38e-05	0.000227	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTCH1—muscle cancer	1.37e-05	0.000226	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—FOXO4—muscle cancer	1.35e-05	0.000223	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—VEGFA—muscle cancer	1.34e-05	0.000221	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—FH—muscle cancer	1.33e-05	0.000219	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—FOXO4—muscle cancer	1.33e-05	0.000219	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CNR1—muscle cancer	1.32e-05	0.000218	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CNR1—muscle cancer	1.3e-05	0.000215	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IGF2—muscle cancer	1.28e-05	0.000212	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTCH1—muscle cancer	1.27e-05	0.00021	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.24e-05	0.000204	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—MED12—muscle cancer	1.22e-05	0.000201	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—FOXO1—muscle cancer	1.18e-05	0.000195	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—FOXO4—muscle cancer	1.18e-05	0.000195	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IGF2—muscle cancer	1.17e-05	0.000193	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IGF2—muscle cancer	1.16e-05	0.000191	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CNR1—muscle cancer	1.16e-05	0.000191	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—MED12—muscle cancer	1.15e-05	0.00019	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IGF2—muscle cancer	1.14e-05	0.000189	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—MED12—muscle cancer	1.14e-05	0.000188	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ENO2—muscle cancer	1.11e-05	0.000183	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FOXO4—muscle cancer	1.09e-05	0.000181	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.09e-05	0.00018	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MDM2—muscle cancer	1.09e-05	0.00018	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—VEGFA—muscle cancer	1.09e-05	0.000179	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MDM2—muscle cancer	1.09e-05	0.000179	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—muscle cancer	1.08e-05	0.000179	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IGF2—muscle cancer	1.08e-05	0.000179	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—FOXO1—muscle cancer	1.08e-05	0.000178	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CNR1—muscle cancer	1.07e-05	0.000177	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—FOXO1—muscle cancer	1.07e-05	0.000176	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IGF2—muscle cancer	1.06e-05	0.000176	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—FOXO1—muscle cancer	1.05e-05	0.000174	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ENO2—muscle cancer	1.05e-05	0.000173	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ENO2—muscle cancer	1.04e-05	0.000171	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—muscle cancer	1.01e-05	0.000167	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—FOXO1—muscle cancer	9.96e-06	0.000164	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—FOXO1—muscle cancer	9.8e-06	0.000162	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MED12—muscle cancer	9.73e-06	0.000161	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IGF2—muscle cancer	9.46e-06	0.000156	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KIT—muscle cancer	8.99e-06	0.000148	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ENO2—muscle cancer	8.87e-06	0.000146	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IGF2—muscle cancer	8.79e-06	0.000145	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—FOXO1—muscle cancer	8.7e-06	0.000144	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—VEGFA—muscle cancer	8.26e-06	0.000136	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—muscle cancer	8.21e-06	0.000136	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KIT—muscle cancer	8.2e-06	0.000135	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KIT—muscle cancer	8.12e-06	0.000134	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.11e-06	0.000134	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FOXO1—muscle cancer	8.09e-06	0.000133	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KIT—muscle cancer	8.02e-06	0.000132	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KIT—muscle cancer	7.59e-06	0.000125	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MED12—muscle cancer	7.51e-06	0.000124	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KIT—muscle cancer	7.47e-06	0.000123	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MDM2—muscle cancer	7.08e-06	0.000117	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.93e-06	0.000114	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTGS2—muscle cancer	6.89e-06	0.000114	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTGS2—muscle cancer	6.87e-06	0.000113	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ENO2—muscle cancer	6.84e-06	0.000113	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KIT—muscle cancer	6.63e-06	0.000109	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MDM2—muscle cancer	6.45e-06	0.000107	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MDM2—muscle cancer	6.4e-06	0.000106	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MDM2—muscle cancer	6.31e-06	0.000104	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—muscle cancer	6.24e-06	0.000103	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—muscle cancer	6.23e-06	0.000103	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KIT—muscle cancer	6.16e-06	0.000102	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MDM2—muscle cancer	5.97e-06	9.86e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MDM2—muscle cancer	5.88e-06	9.71e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—muscle cancer	5.59e-06	9.24e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—muscle cancer	5.38e-06	8.88e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MDM2—muscle cancer	5.22e-06	8.62e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—muscle cancer	5.14e-06	8.48e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—muscle cancer	4.9e-06	8.09e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—muscle cancer	4.86e-06	8.02e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MDM2—muscle cancer	4.85e-06	8.01e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—muscle cancer	4.84e-06	8e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—muscle cancer	4.79e-06	7.92e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—muscle cancer	4.54e-06	7.49e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—muscle cancer	4.46e-06	7.37e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—muscle cancer	4.06e-06	6.71e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—muscle cancer	3.97e-06	6.55e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—muscle cancer	3.87e-06	6.39e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—muscle cancer	3.7e-06	6.11e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—muscle cancer	3.68e-06	6.08e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—muscle cancer	3.67e-06	6.06e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—muscle cancer	3.65e-06	6.02e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—muscle cancer	3.62e-06	5.98e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—muscle cancer	3.61e-06	5.97e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—muscle cancer	3.43e-06	5.66e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—muscle cancer	3.37e-06	5.57e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—muscle cancer	3.09e-06	5.1e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—muscle cancer	3e-06	4.95e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—muscle cancer	2.78e-06	4.6e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—muscle cancer	2.38e-06	3.93e-05	CbGpPWpGaD
